Further US Patent Granted for Cynata Cymerus Technology
Filed with ASX · · 1 page · English
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- FDA Grants Orphan Drug Designation to Cyanta for CYP-001
- Excellent Data from Final Preliminary Evaluation Period
- Cynata Engineered MSC Study Review Reveals Promising Results
- December 2017 Quarterly Report
- Cynata Treats First Patient in Cohort B
Later from Cynata Therapeutics
- CYP Completes Patent Application related to CAR-T Therapy
- March 2018 Quarterly Report
- Notice of Allowance from EPO for Patent Application
- Enrolment Completed in Cynatas Phase 1 Clinical Trial
- $5.2m placement of shares to Fidelity International
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics